目的 考察康復新液聯(lián)合四聯(lián)療法治療幽門螺桿菌陽性胃潰瘍的臨床療效。方法 選擇2019年2月—2020年2月在河南大學淮河醫(yī)院就診治療的60例幽門螺桿菌陽性胃潰瘍患者，按照入院先后順序分為對照組和治療組，每組各30例。對照組患者采用四聯(lián)療法治療：口服阿莫西林膠囊，1.0 g/次，2次/d；口服克拉霉素緩釋片，0.5 g/次，2次/d；口服枸櫞酸鉍鉀顆粒，4袋/d，3餐前1袋，晚餐2 h后服用1袋；口服泮托拉唑鈉腸溶膠囊，40 mg/次，2次/d；治療2周后停用其他藥物，僅口服泮托拉唑鈉腸溶膠囊。治療組患者在對照組治療的基礎上口服康復新液，10～15 mL/次，1次/d。兩組連續(xù)治療6周。觀察兩組患者臨床療效，比較兩組治療前后的血清氧化應激因子、炎性因子、胃腸道激素水平。結果 治療后，治療組總有效率（93.33%）較對照組（76.67%）高，組間有差異（P<0.05）。治療后，兩組患者的丙二醛（MDA）、脂質過氧化物（LPO）水平與同組治療前數(shù)據(jù)相比較顯著降低，一氧化氮（NO）水平顯著升高，差異有統(tǒng)計學意義（P<0.05）；治療后，治療組患者血清氧化應激因子水平均顯著優(yōu)于對照組，組間比較有顯著差異（P<0.05）。治療后，兩組患者白細胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、C反應蛋白（CRP）水平與同組治療前數(shù)據(jù)相比較均顯著降低，差異有顯著性意義（P<0.05）；治療后，治療組患者的IL-6、TNF-α、CRP水平均顯著低于對照組，組間比較差異有顯著性（P<0.05）。治療后，兩組患者血清胃動素（MTL）、胃泌素（GAS）水平與同組治療前相比較均顯著降低，差異有統(tǒng)計學意義（P<0.05）；治療后，治療組患者的血清MTL、GAS水平明顯低于對照組，組間有差異（P<0.05）。治療后，治療組幽門螺桿菌根除率、潰瘍愈合率分別為90.00%、73.33%，分別高于對照組的76.66%、56.66%，組間有差異（P<0.05）。結論 康復新液聯(lián)合四聯(lián)療法治療幽門螺桿菌陽性胃潰瘍具有較好的臨床療效，可以減輕患者的炎性反應，改善氧化應激狀態(tài)，對胃腸激素起到了較好的調節(jié)作用，安全性較高，值得在臨床上借鑒。

Objective To study the effect of Kangfuxin Liquid combined with quadruple therapy in treatment of Helicobacter pylori positive gastric ulcer. Methods Patients (60 cases) with H.pylori positive gastric ulcer in Huaihe Hospital of Henan University from February 2019 to February 2020 were divided into control and treatment groups according to order of admission, and each group had 30 cases. Patients in the control group were given quadruple therapy:patients in the control group were po administered with Amoxicillin Capsules, twice daily, and patients in the control group were po administered with Clarithromycin Sustained Release Tablets, 0.5 g/time, twice daily, and patients in the control group were po administered with Bismuth Potassium Citrate Granules, 1 bag/time, 4 bags daily, 1 bag before three meals, and 1 bag 2 hours after dinner, and patients in the control group were po administered with Pantoprazole Sodium Enteric-Coated Capsules, 40 mg/time, twice daily. Other drugs were stopped after 2 weeks of treatment, and only Pantoprazole Sodium Enteric-Coated Capsules were taken. Patients in the treatment group were po administered with Kangfuxin Liquid on the basis of the control group, 10-15 mL/time, once daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacies were evaluated, and the serum levels of oxidative stress factors, inflammatory factors, and gastrointestinal hormone in two groups were compared. Results After treatment, the total effective rate of the treatment group (93.33%) was higher than that of the control group (76.67%), and there was difference between two groups (P < 0.05). After treatment, the levels of MDA and LPO in two groups were significantly lower than those before treatment in the same group, and the level of NO in two groups was significantly higher than that before treatment (P < 0.05). After treatment, the serum levels of oxidative stress factors in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the levels of IL-6, TNF-α, and CRP in two groups were significantly lower than those before treatment (P < 0.05). After treatment, the levels of IL-6, TNF-α, and CRP in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of MTL and GAS in two groups were significantly lower than those before treatment (P < 0.05). After treatment, the levels of MTL and GAS in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the H. pylori eradication rate and the ulcer healing rate in the treatment group were 90% and 73.33%, respectively, which were higher than those in the control group (76.66% and 56.66%), and there were differences between two groups (P < 0.05). Conclusion Kangfuxin Liquid combined with quadruple therapy has clinical curative effect in treatment of H. pylori positive gastric ulcer, can reduce the inflammatory reaction of patients, improve the oxidative stress state, and play a better regulatory role in gastrointestinal hormones, with high safety, which is worthy of clinical reference.

R975

國家自然科學基金資助項目（81700187）